To see the other types of publications on this topic, follow the link: Saint-Quentin, France.
Journal articles on the topic 'Saint-Quentin, France'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 17 journal articles for your research on the topic 'Saint-Quentin, France.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Dusaussoy, Bruno. "Le comte de Saint-Quentin, ambassadeur de France à Washington, février 1938-septembre 1940." Bulletin de l'Institut Pierre Renouvin 27, no. 1 (2008): 91. http://dx.doi.org/10.3917/bipr.027.0091.
Full text
2
Ganz, D. "Manuscrits dates des bibliotheques de France, II: Laon, Saint-Quentin, Soissons, by Denis Muzerelle." English Historical Review 129, no. 541 (December 1, 2014): 1456–57. http://dx.doi.org/10.1093/ehr/ceu296.
Full text
3
Sapin, Chr. "La présence du corps saint dans le sanctuaire. Réflexions sur les contraintes et les aménagements entre Ve et XIe siècle, à partir de l’exemple de Saint-Quentin (Aisne, France)." Hortus Artium Medievalium 15, no. 1 (May 2009): 105–16. http://dx.doi.org/10.1484/j.ham.3.47.
Full text
4
박선욱. "Etude sur la forme et l’image du centre en tant qu’espace de consommation:Focused sur la ville de Saint-Quentin-en-Yvelines en France." ASSOCIATION CULTURELLE FRANC0-COREENNE 40, no. 1 (March 2019): 205–28. http://dx.doi.org/10.18022/acfco.2019.40.1.008.
Full text
5
Maclouf, Pierre. "La restructuration économique et l’ancrage territorial de la crise de l’État-providence." I. Restructurations économiques et rapports sociaux, no. 13 (January 15, 2016): 9–17. http://dx.doi.org/10.7202/1034533ar.
Full textAbstract:
Le thème de la « crise de l’État-providence » est abordé ici sous l’angle du pouvoir local. Le niveau étant défini comme « le cadre concret où se nouent les relations entre production économique et appropriation, par les groupes bénéficiaires, des transferts sociaux ». Reprenant les résultats d’une recherche menée à l’Institut d’études politiques de Paris, l’auteur se penche sur trois milieux de vie différents situés dans le contexte français : un bassin d’emploi de vieille souche industrielle, Saint-Quentin, des cantons ruraux du Limousin et la commune d’Arles dans le sud-est de la France, qui repose sur une économie diversifiée. L’étude des relations entre l’État et les collectivités locales à partir de ces trois exemples permettent de bien voir qu’il existe en fait un ancrage territorial de l’État que les mises à jour des logiques générales ont souvent tendance à gommer. Il ressort au contraire que l’État-providence s’est construit en intégrant, dans l’élaboration de ses politiques sociales, les particularismes locaux. En conclusion l’auteur propose quelques perspectives en vue de surmonter la crise actuelle de l’État-providence. Il aborde alors un principe de « reterritorialisation » du social ouvert sur le développement et la participation populaire. Le défi est de ne pas se limiter à une « simple régulation de la crise ».
6
Merkley, Paul. "Josquin Desprez in Ferrara." Journal of Musicology 18, no. 4 (2001): 544–83. http://dx.doi.org/10.1525/jm.2001.18.4.544.
Full textAbstract:
The recovery of two notarial documents prepared in Ferrara on behalf of Josquin Desprez soon after his arrival in that city in the spring of 1503 demonstrates his intentions at that time to obtain the provosty of Notre Dame of Condéé and reveals the complicated exchange of benefices that brought about that result. The documents name Loyset Compèère and Pierre Duwez as respondents to Desprez in a quadrangular exchange of positions. In this transaction Josquin appointed the dean of the chapter of Condéé to resign the benefice he held in the collegiate church of Saint-Quentin. Since this was a position over which the King of France enjoyed full legal rights of collation, Josquin ordered the position to be surrendered to that monarch or his confessor, rather than to the pope. Accordingly these documents provide a very strong indication that Louis XII of France was the composer's patron before he came to Ferrara and that the king approved of this benefice exchange. In light of these implications, aspects of the composer's career before and after his Ferrarese service are reconsidered, including occasions on which he composed works for patrons in the French and imperial networks, such as Margaret of Austria, and his collaboration with the poet Jean Lemaire de Belges. Repertoire from Josquin's year in Ferrara is discussed, along with the Hercules Mass. Sections of his setting of the psalm Miserere mei deus are commented on, in connection both to a Biblical passage concordant with a verse of the psalm and to remarks by the theorist Glareanus. The expressive qualities of the Miserere are related to the devotional and ceremonial of duke Ercole, especially in the context of the outbreak of the plague in Ferrara.
7
Pilorget, Julie. "Sébastien Hamel, La justice dans une ville du Nord du royaume de France au Moyen Âge. Étude comparée sur la pratique judiciaire à Saint-Quentin, Turnhout, Brepols, 2011 , 411 p." Histoire urbaine 43, no. 2 (2015): 187. http://dx.doi.org/10.3917/rhu.043.0187.
Full text
8
Löffler, Anette. "Catalogue des manuscrits notés du Moyen Âge conservés dans les bibliothèques publiques de France 4. Collections du Nord – Pas-de-Calais et de Picardie II: Chantilly, Douai, Laon, Lille, Saint-Omer, Saint-Quentin, Soissons, Valenciennes, written by Christian Meyer." Church History and Religious Culture 97, no. 1 (2017): 103–5. http://dx.doi.org/10.1163/18712428-09701008.
Full text
9
Donadieu, Jean, Blandine Beaupain, Hélène Lapillonne, Odile Fenneteau, Flore Sicre de Fontbrune, Yves Bertrand, Nathalie Aladjidi, et al. "How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry." Blood 136, Supplement 1 (November 5, 2020): 40–41. http://dx.doi.org/10.1182/blood-2020-135912.
Full textAbstract:
Introduction: Congenital neutropenia (CN) is characterized by chronic neutropenia caused by a constitutional genetic defect and can be considered an orphan disease. Nationwide estimations of its incidence and prevalence are poorly documented but would provide key information to better follow-up of CN patients. Notably, orphan-drug status also is accorded based on such epidemiological parameters. Methods: The French Severe Chronic Neutropenia Registry (FSCNR) has prospectively enrolled CN patients since 1993, with multiple source verifications in France of that information: pediatric and adult hemato-immunology units, diagnostic labs... We also actively collect all cases followed in France, regardless of the healthcare facility monitoring the patient. To calculate incidence at birth, we considered subjects born between 1/1/1995 and 12/31/2017, because information completeness has been validated for this 22-year period. Number of births per year was provided by the French National Institute of Statistics and Economic Studies (INSEE). We used American College of Medical Genetics class 4 and 5 variants for genetic classification and the overall CN classification developed elsewhere.1 To estimate expected prevalence, we assumed 50-year life expectancy for these patients and compared ongoing enrolment to the prevalence estimation and calculated FNSCR coverage. A Poisson distribution was assumed. Results: On 15 July 2020, the FSCNR had identified 3205 patients. Reasons for non-enrolment of 2096 were, mainly: autoimmune neutropenia (n=501), foreign residency (n=214), other diagnosis (n=882) and diagnostic work-up not completed (n=249). Among the 1109 patients who fulfilled Chronic Neutropenia criteria, 242 had idiopathic neutropenia2 and 867 patients were considered to have CN1. Global results are presented in Table 1. In France, the CN incidence at birth (all subtypes combined) was 2.6×10-5 (95% CI: 2.04-2.8×10-5), which represents a mean of 23 new cases/year in a country with ~870,000 births/year. For all CN combined, the expected prevalence, assuming 50-year life expectancy, would be 1131 cases in a country of 65×106 inhabitants while the FCSNR currently has 867 cases enrolled or an estimated 77% nationwide coverage. Based on our results and our assumptions for life expectancy, estimated prevalence of CN for 10 millions inhabitants is therefore 174 CN. Genetic subtype representation is as follows: 20% SBDS, 17% ELANE (8% cyclic, 9% permanent), 9% GATA2, 7% SLC37A4, ~4-5% each of TAZ and CXCR4 and VPS13B, while the other subtypes are even rarer. At present, no cause has been identified for 25% of the cases. Conclusion: The results of this analysis provide an estimation of the major CN-descriptive epidemiological parameters and the relative frequencies of several subtypes. Despite the FSCNR's quite large registry, we estimate that about a quarter of the prevalent cases in France were missed, mainly those followed as adults. References 1 Donadieu J, Beaupain B, Fenneteau O, Bellanne-Chantelot C. Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br.J.Haematol. 2017; 179(4): 557-574. 2 Sicre De Fontbrune F, Moignet A, Beaupain B et al. Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood 2015; 126(14): 1643-1650. Acknowledgments: The French SCN registry is supported by grants from Amgen, Chugai, Prolong Pharma, X4 Pharma, Inserm, the Association 111 les Arts, the Association RMHE, the Association Sportive de Saint Quentin Fallavier. The authors thank the association IRIS and Mrs Grosjean and Mr Gonnot(ASSQF), the association Barth France for their support. Disclosures Sicre de Fontbrune: Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. cohen Beaussant:X4 Pharmaceuticals, Inc.: Current Employment.
10
Le Bourhis, D., S. Camugli, P. Salvetti, L. Schibler, and E. Schmitt. "180 ASSESSMENT OF BULL SEMEN QUALITY LOADED IN NEW SensiTemp STRAWS USING SEMEN AND IN VITRO PRODUCTION TECHNOLOGIES." Reproduction, Fertility and Development 28, no. 2 (2016): 221. http://dx.doi.org/10.1071/rdv28n2ab180.
Full textAbstract:
SensiTemp, a new in vitro maturation (IMV) bull straw concept, presents the advantage of colour changing while the straw is thawed. The colour of frozen straws is blue and straws start to become white when the temperature reaches 33°C, with a complete change of colour at 37°C. The objective of this study is to assess sperm quality after thawing of semen frozen in SensiTemp from 2 bulls, by analysing, in experiment 1, sperm motility and membrane integrity using computer-assisted semen analysis (CASA) and flow cytometry (FC), and, in experiment 2, the in vitro embryo production (IVP) using IVP technologies [IVM, IVF, and in vitro culture (IVC)]. The ejaculates of 2 bulls, selected during preliminary experiments on high in vitro fertility, were harvested at CIA L’Aigle, France, and split ejaculates were frozen in experimental (SensiTemp) and conventional (control) straws. In experiment 1 after thawing semen from the 2 types of straws (5 pooled straws each; 2 replicates), motility was assessed using the IVOS CASA system (Hamilton Thorne Inc., Beverly, MA, USA) and membrane integrity was evaluated through FC with Cytosoft software (Millipore-Guava Technologies Inc., Hayward, CA, USA). In experiment 2, IVF was used to evaluate the non-toxicity of SensiTemp and control straws. Cumulus-oocyte complexes (COC; n = 1178; 4 replicates) collected from slaughterhouse ovaries were matured in IVM medium (TCM-199 with bicarbonate, Sigma-Aldrich, Saint Quentin Fallavier, France; 10 µg mL–1 FSH-LH, Reprobiol, Liège, Belgium; and 10% FCS, Thermo Fisher, Illkirch, France) for 22 h. After fertilization, presumptive zygotes of each group (SensiTemp and control for each bull) were cultured in synthetic oviduct fluid medium (SOF, Minitube, Tiefenbach, Germany) with 1% estrous cow serum (ECS) and 0.6% BSA (Sigma-Aldrich, France) up to 8 days. All cultures were conducted at 38.5C in 5% CO2, and 5% O2. The cleavage and blastocysts rates were evaluated on Days 3 and 7, respectively, for each group. Embryo quality was recorded on Day 7 according to the IETS evaluation. Data from each bull were analysed separately using the chi-squared test (P < 0.05). In experiment 1, neither sperm motility from bull 1 (61.2 and 60.5%) and bull 2 (66.2 and 66.5%) nor membrane integrity from bull 1 (58.6 and 52.2%) and bull 2 (61.0 and 61.9%) were different between SensiTemp and control, respectively. Results from experiment 2 showed no difference (P > 0.05) in cleavage rate between SensiTemp and control for the 2 bulls: 92.1 and 91.7% for bull 1 and 94.2 and 94.6% for bull 2 respectively. The blastocysts rate on Day 7 did not differ (P > 0.05) among groups (47.5, 47.1 and 51.3, 50.4% for SensiTemp and control bull 1 and bull 2, respectively) nor the quality of embryos retrieved in the different groups: 25.4, 23.3, and 30.8, 29.6% in grade 1 embryo for SensiTemp and control bull 1 and bull 2, respectively. Those results demonstrate, in vitro, that the new SensiTemp straws were non-toxic and did not affect the semen quality after thawing nor did the SensiTemp straws affect the ability of sperm cells to fertilize oocytes and produce 8-day-old embryos.
11
Harding, L. K. "The effects of low and very low doses of ionizing radiation on human health. Proceedings of the first international symposium held at the University of Versailles, Saint Quentin en Yvelines, France on 17th and 18th June 1999. 2000." European Journal of Nuclear Medicine 28, no. 11 (September 26, 2001): 1706. http://dx.doi.org/10.1007/s002590100634.
Full text
12
Degrelle, S., I. Hue, and J. P. Renard. "122 USE OF A DAY-14 EMBRYONIC ARRAY TO STUDY THE ELONGATION PHASE OF THE BOVINE EMBRYO." Reproduction, Fertility and Development 17, no. 2 (2005): 211. http://dx.doi.org/10.1071/rdv17n2ab122.
Full textAbstract:
In cattle, more than 30% of embryonic losses observed after artificial insemination (AI) have an early origin, coincident with a marked elongation of the trophoblast which occurs before implantation, between the 13th and 19th days of pregnancy. During this exponential growth phase, physiological interactions essential for pregnancy are established between the embryo and the uterus. Our work focuses on the identification of transcripts that regulate this key developmental period in several domestic species. For that, we generated a nylon membrane that contained 1920 gridded inserts originating from a Day-14 bovine embryo cDNA library (dbEST ID.15979; Hue et al., in preparation). Gene expression profiles in trophoblasts of increasing sizes were compared using ovoid (10–18-mm), tubular (50–60-mm), and early filamentous (140–150-mm) stages as complex probes. Trophoblasts were collected and immediately snap-frozen. RNA extractions were performed using RNAplus (Quantum Appligene, Illkirch 67402, France). Due to the scarce amount of mRNA per embryo, amplified material was used to hybridize the array. For that, antisense-RNA (aRNA) and cDNA were generated starting from 1 μg of total RNA, as described by the MessageAmp aRNA kit instructions (Ambion, Rusin, TX 78744, USA) and according to Revel et al. (1995 Zygote 3, 241–250). Five hundred nanograms of aRNA or cDNA were random-primed and labelled with 33P-alpha-dATP [aRNA, according to the procedure of Decraene et al. 1999 BioTechniques 27, 962–966; cDNA using the Atlas SMART Probe Amplification kit, (Clontech, Osyme, Saint Quentin Yvelines 78053, France)]. For each protocol, two probes were generated independently and each of these probes was hybridized to four identical membranes according to Clontech instructions. These were then exposed to phosphoscreens and scanned after 7 days. Quantifications were done using ImaGene 5.1 (BioDiscovery, El Segundo, CA 90245, USA) and statistically analyzed with the AnovArray package freely available for non-commercial use at http://www.jouy.inra.fr/stat/AnovArray (Piot et al. 2004 Bioinformatics, submitted). Reproducibility of the two protocols used to amplify material (aRNA and cDNA) was confirmed by slot blot quantifications before labelling. The hybridization profiles generated for each protocol (8 membranes per stage) were also highly reproducible (0.95 < r < 0.97), allowing a global statistical analysis with the AnovArray package. The results of the analysis of variance (ANOVA), including the correction for False Discovery Rate (FDR < 0.05), led to the identification of several bovine ESTs with unknown function that are differentially expressed during the rapid phase of trophoblastic elongation. Since genes, already known to be involved during elongation (IFN tau, Kunitz inhibitor), were also found differentially expressed in this study, this genomic approach using amplified complex probes is reliable to search for new markers of early developmental stages in cattle. Additionally, a thorough analysis of those markers may define them as interesting tools to assess the quality of embryonic development after AI, IVF (in vitro fertilisation), or SNT (somatic nuclear transfer). This work was supported by EU (BOI4-CT95-0190) and INRA-AGENA (AIPP00183) grants.
13
Martignoles, Jean-Alain, Pierre Hirsch, Blandine Beaupain, Thomas Longval, Nawa Hachem, Mira El-Khoury, Sophie Kaltenbach, et al. "Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients." Blood 136, Supplement 1 (November 5, 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-138540.
Full textAbstract:
Introduction : Hematological complications (HC) as Aplastic anemia (AA) and myelodysplasia and acute leukemia (MDS/AL) are frequent and life threatening in patients with Shwachman Diamond Syndrome (SDS) with SBDS mutations. The therapy of such events is based on Hematopoetic stem cell transplantation (HSCT), which results remain quite poor, especially in case of malignancy. So far, it is difficult to anticipate to such HC and a lot is expected from the study of clonal evolution prior HC. Methods: A Targeted panel of 43 genes involved in MDS/AL (sensibility 1%) has been evaluated in 80 patients with SBDS mutation, representative of a nation based cohort of 154 patients. This cross sectional study has been completed by a prospective study for 40 patients evaluated at several time points. Results: The evaluation was performed in various situations: steady state i.e. no haematological complication, in MDS/AL and AA and lastly after HSCT. At the first evaluation, somatic mutation was found in 21 patients (30%) among the 70 in steady state and in 7 of the 8 cases with HC (6/6 cases with MDS/AL, in 1 among the 2 cases with AA) while the 1 of the 2 patients long term survivors after HSCT have no mutation and the other one kept a TP53 clone with a normal blood count and a low (1.5%) variant allele frequency (VAF). Among the 40 patients with several time points, 17 have a mutation at the first time points, but 10 others had additional mutation later. Globally, the most frequent gene involved was TP53 (82%) while mutations in other genes have been observed rarely. VAF in patients with vs without HC is lower (median VAF 0% vs 22.8% respectively p < 0.001) . Complex caryotype, monosomy 7, Iso7q were associated with P53 clone while in Del20q, 8 patients out 14 have a P53 mutations. The comparison between blood and bone marrow results allow the possibility to monitor such mutations in blood. Clonal evolution in one patient who presents a MDS in the course of the follow up had shown a competition between clones. Conclusion: Acquired TP53 is extremely frequent in patients with SBDS mutations, even in the absence of HC, but the prevalence as well as the VAF increased in case of HC. When sequential evaluation could be performed, competition between clones is frequent and a clinical decision remains therefore difficult, just on the evaluation of a time point. Acknowledgments: The French SCN registry is supported by grants from Amgen, Chugai, Prolong Pharma, X4 Pharma, Inserm, the Association 111 les Arts, the Association RMHE, the Association Sportive de Saint Quentin Fallavier. The authors thank the association IRIS and Mrs Grosjean and Mr Gonnot(ASSQF), the association Barth France for their support. Disclosures Sicre de Fontbrune: Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. Renard:Jazz Pharmaceuticals: Research Funding. Tournilhac:ABBVIE: Consultancy, Honoraria, Other: Travle grant; INNATE Pharma: Consultancy, Honoraria; GILEAD: Consultancy, Honoraria, Other: Travel Grant; Takeda: Consultancy, Honoraria, Other: Travel grant; Janssen: Consultancy, Honoraria, Other: Travel grant.
14
Donadieu, Jean, Fares bou Mitri, Blandine Beaupain, Yves Bertrand, Pierre Simon Rohrlich, Nathalie Aladjidi, Alexia Rouland, et al. "Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry." Blood 136, Supplement 1 (November 5, 2020): 15–16. http://dx.doi.org/10.1182/blood-2020-136053.
Full textAbstract:
Introduction: Congenital neutropenia (CN) is characterized by chronic neutropenia due to a constitutional genetic defect.1 To date, these diseases have not been considered to be frequently associated with malignant solid tumors, unlike the risk of secondary myelodysplastic syndrome leukemia, which is well-known in CN. Methods: The French Severe Chronic Neutropenia Registry (FSCNR) has prospectively enrolled CN patients since 1993. Solid tumors, identified during routine patient follow-up, were classified according to WHO criteria. We included localized lymphoma in the spectrum of malignant solid tumors. We calculated the incidence of malignant solid tumors in a cohort of CN patients. Results: Among 868 patients with various CN subtypes followed for a total of 16617 person-years, 24 patients who developed a malignant solid tumor were identified. Those cancers are described in Table 1, including the CN genetic anomaly. Cancers were almost always diagnosed in adulthood, with median age at diagnosis of 38.1 (range 10-72) years; only 3 cancers were diagnosed before age of 20 years. The cancer rate was 1.2% at 30 years of age, 7% at 40 years and 24% at 50 years (Fig. 1A). The risk-of-cancer percentages depended mainly on the associated genetic deficiency. Solid tumors were roughly distributed as follows: 33% among WHIM (CXCR4) patients, 5.3% among GATA2 patients, 2.7% among ELANE patients, 1.9 % among SBDS patients and 0.8% among for all other subtypes combined (Fig. 1B). Human papillomavirus (HPV) was the cause of cancer for 2/5 in WHIM patients and 2/6 in GATA2 patients. Three Lymphoma were identified, one in GATA2 patient and 2 in WHIM patients. Notably, our cohort's follow-up is skewed to the right, with less efficient monitoring of adults, with still limited long-term follow-up beyond 40 years. Therefore, we probably underestimated the solid-tumor risk in CN patients, as many patients, if alive, are no longer followed in hematology centers. Among 103 patients who underwent hematopoietic stem-cell transplantation (HSCT), 76 were long-term survivors. None of them developed solid tumors, which differs strikingly from the high malignancy risk associated with Fanconi anemia post-HSCT. Lastly, the FSCNR also includes and follows patients with idiopathic neutropenia. Among the 232 idiopathic neutropenia patients, followed for a total of 2866 person-years, no malignancy has been observed so far. Conclusion: Our data lead us to advance that CN patients should be considered at risk of developing solid cancers, especially after the age of 30 years. This risk, at first glance, depended on the CN-associated genetic anomaly, with CXCR4 mutation, GATA2, SBDS and ELANE being the most frequent. HSCT was not associated with a higher risk and may, in contrast, be protective. These findings warrant confirmation but represent a compelling reason to prolong follow-up into adulthood of CN patients diagnosed during childhood. No indication was found of a specific high solid-tumor risk associated with idiopathic neutropenia. Reference Donadieu J, Beaupain B, Fenneteau O, Bellanne-Chantelot C. Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br.J.Haematol. 2017; 179(4): 557-574. Acknowledgments: The French SCN registry is supported by grants from Amgen, Chugai, Prolong Pharma, X4 Pharma, Inserm, the Association 111 les Arts, the Association RMHE, the Association Sportive de Saint Quentin Fallavier. The authors thank the association IRIS and Mrs Grosjean and Mr Gonnot(ASSQF), the association Barth France for their support. Disclosures Hermine: Roche: Consultancy; Celgene BMS: Consultancy, Research Funding; AB Science: Consultancy, Current equity holder in publicly-traded company, Honoraria, Patents & Royalties, Research Funding; Alexion: Research Funding; Novartis: Research Funding. Blaise:Jazz Pharmaceuticals: Honoraria. Sicre de Fontbrune:Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. cohen Beaussant:X4 Pharmaceuticals, Inc.: Current Employment.
15
Donadieu, Jean, Blandine Beaupain, Fares bou Mitri, Flore Sicre de Fontbrune, Despina Moushous, Thierry Lamy, Aline Moignet Autrel, Elodie Gouache, Marlène Pasquet, and Christine Bellanne-Chantelot. "Lenograstim and Filgrastim Have a Similar Efficacy and Safety Profile in the Treatment of Chronic Neutropenia. a Study for the French SCN Registry:." Blood 136, Supplement 1 (November 5, 2020): 17–18. http://dx.doi.org/10.1182/blood-2020-138476.
Full textAbstract:
Introduction: GCSF is a key drug in the medical management of chronic neutropenia (ChrN). Two major marketed forms of G-CSF are used. Filgrastim (F), marketed initially with the brand name Neupogen®;, now available with generic presentation, is a non-glycosylated GCSF. A pegylated (PegF) formulation of F exists too. Lenograstim (L) is the second form of bio-engineering GCSF and is glycosylated and marketed with the brand name Granocyte®. L is distributed in 263 µg and 105 µg vials while F is distributed in 300 and 480 µg vials. L and F have a similar PK profile (1/2 time ~3.7 h), contrary to PegF (1/2 time 42H). Here we compare the efficacy and safety of F and L in ChrN. METHODS The French Severe Chronic Neutropenia Registry (FSCNR) since 1993 prospectively monitors patients with ChrN and collects routinely information about G-CSF therapy (type of product including the Brand names, dose per injection, number of injections, duration of the period of daily treatment, infections, blood counts, side effects..)(1). On 1 October 2019, the FSCNR had enrolled 1068 patients with ChrN (idiopathic neutropenia(2) n=231 and Congenital neutropenia(3) n=837 patients). To take into account individual changes in G-CSF regimens, for a given patient, treatment was divided into elementary periods during which the characteristics of G-CSF treatment remained constant. Several parameters were calculated by summing up the elementary periods: duration of follow-up after G-CSF start, Cumulative duration, Cumulative dose, Time averaged dose (TAD). Three treatment groups were defined according to the type of G-CSF received: "group F" for patients who received only F, "group L" for patients who received only L , "group FL" for patients who received both F and L in succession. As there are no guidelines for GCSF prescription (F or L), even if L is here prescribed off-labelled, treating physician made is own choice. Because PegF have a very specific PK profile, we excluded the Peg F periods from this analysis (only 29 patients have received PegF as part of their therapy). The analysis presented here is limited only to the "L group', the "F group' and the "FL group'. 434 of the 1068 patients with ChrN have received a GCSF therapy: 172 received Lenograstim alone (group L), 148 Filgrastim alone (group F) and 112 received both cytokines consecutively (group FL). RESULTS : The key parameters defining the disease, the severity of the clinical and hematological presentation, the median neutrophil count, the proportion of patients with bone marrow blockage and the number of severe and oral infections was similar between the 3 patient groups (table 1). For group FL and more over the L group the median age at the start of G-CSF was younger (p<0.001). Such differences may be related to the availability, for L, of a smaller vial, more adapted to the prescription of GCSF in infants. At contrary, the TAD received by the patients was similar between the 3 treatment groups (5.5 µg/kg vs 5 and 5 in FL, L and F respectively, p=0.14). With regards to the efficacy, by taking in consideration both hematological parameters like neutrophil count, the rate of failure, as well clinical endpoints like the rate of stomatological and severe infections, we failed to find any differences between L and F groups and among the FL group, between F and L periods. Lastly, rate of side effects, both major side effects like death (mostly not related to GCSF), Myelodysplasia or leukemia, or mild, like bone pains were not different between F and L. Patients from FL have a higher rate of side effects, probably because physicians tried to avoid minor side effects by drug switch. Conclusions: The efficacy profile as well as the safety profile of Lenograstim is indistinguishable from that of Filgrastim in ChrN. The availability of Lenograstim in small vial represent a pragmatic advantage to treat infants as well as patients who are requiring only little amount of GCSF. References J. Donadieu et al., Haematologica90, 45 (2005).F. Sicre De Fontbrune et al., Blood126, 1643 (2015).J. Donadieu, B. Beaupain, O. Fenneteau, C. Bellanne-Chantelot, Br. J. Haematol.179, 557 (2017). Acknowledgments: The French SCN registry is supported by grants from Amgen, Chugai, Prolong Pharma, X4 Pharma, Inserm, the Association 111 les Arts, the Association RMHE, the Association Sportive de Saint Quentin Fallavier. The authors thank the association IRIS and Mrs Grosjean and Mr Gonnot(ASSQF), the association Barth France for their support. Disclosures Sicre de Fontbrune: Alexion Pharmaceuticals Inc.: Honoraria, Research Funding.
16
Vié, Arnaud. "Strategies to optimize pump efficiency in sugar manufacturing." Sugar Industry, 2014, 570–71. http://dx.doi.org/10.36961/si15843.
Full textAbstract:
Based in Saint-Quentin in France, in the heart of one of the most important region for the sugar industry worldwide, Ensival Moret’s history is intertwined with that of the sugar industry. Thanks to a close collaboration with the actors of the sugar industry, Ensival Moret has always accompanied them in their projects in France and worldwide, and has become the leading partner for providing comprehensive pumping solutions for sugar plants and by-products processes.
17
Herr, M., M. El Kassouani, A. Labbe, and L. Josseran. "Participation of medical students in prevention actions: first year of implementation in France." European Journal of Public Health 29, Supplement_4 (November 1, 2019). http://dx.doi.org/10.1093/eurpub/ckz186.541.
Full textAbstract:
Abstract Background Prevention has become an essential part of the health policy in France. Since the autumn 2018, medical students, as well as students in midwifery and paramedics, are required to take part in prevention actions in population. This prevention training is mandatory and aims to increase the number of prevention actions in population and to sensitize medical students to the importance of prevention. National guidelines were published to guide the implementation of this training. Objectives: This communication aims to describe the implementation of this prevention training in the medical school of University Versailles Saint-Quentin-en-Yvelines in France. Results A total of 155 students in third year of medical school were included in the training (2018/2019). The first step was the creation of e-learnings in 9 domains related to prevention: prevention policy in France, communication, project management, addictions, nutrition, physical activity, sexual education, prevention for the children and prevention for the elderly. They were elaborated by medical doctors of different specialties, public health professionals, nurses, and physiotherapists. The second step was the recruitment of voluntary settings to perform prevention acitons. They were mainly schools (n = 24), but also institutions for disabled children or adults (n = 8), health forums (n = 4), the university health center and the local center for social reintegration of young people. The types of actions performed by the students will be presented at the conference. Conclusions Preliminary results indicate a positive feedback from both the students and the voluntary settings. At this stage, recommendations for the future can already be drawn, such as the inclusion of specific training sessions to lead group sessions of various ages or interdisciplinarity in the actions. Key messages The participation of medical students to prevention actions in population has become mandatory in France. Voluntary settings were mainly schools, but also institutions for disabled children or adults.